Get the Stockscreener App
18.36
2.71%
0.485
Denali Therapeutics Inc stock is traded at $18.36, with a volume of 779.34K.
It is up +2.71% in the last 24 hours and down -9.94% over the past month.
Denali Therapeutics Inc is a biotechnology company that is engaged in developing and discovering therapeutics to defeat neurodegenerative diseases. The company's development programs include the LRRK2 Inhibitor Program, which develops brain penetrant small molecule LRRK2 inhibitor product candidates for Parkinson's disease. Its key products include DNL201, DNL151, ATV (Antibody Transport Vehicle), ETV (Enzyme Transport Vehicle), and others. The Company has one operating segment with the goal to discover, develop, and commercializing therapeutics.
See More
Previous Close:
$17.87
Open:
$18.04
24h Volume:
779.34K
Relative Volume:
0.39
Market Cap:
$2.93B
Revenue:
$1.27M
Net Income/Loss:
$-508.02M
P/E Ratio:
-6.3717
EPS:
-2.8807
Net Cash Flow:
$-419.23M
1W Performance:
-1.69%
1M Performance:
-9.94%
6M Performance:
-15.34%
1Y Performance:
+12.54%
1-Day Range:
$18.00
$18.47
1-Week Range:
$17.53
$19.62
52-Week Range:
$13.75
$27.30
Denali Therapeutics Inc Stock (DNLI) Company Profile
Name
Denali Therapeutics Inc
Sector
Industry
Phone
(650) 866-8547
Address
161 OYSTER POINT BLVD., SOUTH SAN FRANCISCO
Compare DNLI vs VRTX, MRNA, REGN, ARGX, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
DNLI
Denali Therapeutics Inc
|
18.36 | 2.93B | 1.27M | -508.02M | -419.23M | -2.8807 |
VRTX
Vertex Pharmaceuticals Inc
|
508.46 | 128.88B | 12.34B | 4.34B | 3.71B | 16.87 |
MRNA
Moderna Inc
|
237.99 | 95.01B | 2.23B | -3.19B | -1.60B | -8.1462 |
REGN
Regeneron Pharmaceuticals Inc
|
800.59 | 82.42B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
849.61 | 53.43B | 4.16B | 1.29B | 734.26M | 19.58 |
ONC
Beone Medicines Ltd Adr
|
372.06 | 42.09B | 5.76B | 514.49M | 1.10B | 4.4813 |
Denali Therapeutics Inc Stock (DNLI) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jul-13-26 | Resumed | JP Morgan | Overweight |
| Mar-26-26 | Reiterated | H.C. Wainwright | Buy |
| Feb-24-26 | Initiated | Wolfe Research | Peer Perform |
| Jan-07-26 | Resumed | UBS | Buy |
| Apr-10-25 | Upgrade | Cantor Fitzgerald | Neutral → Overweight |
| Mar-07-25 | Resumed | Morgan Stanley | Overweight |
| Feb-11-25 | Initiated | Deutsche Bank | Buy |
| Jan-07-25 | Initiated | Robert W. Baird | Outperform |
| Jan-03-25 | Initiated | William Blair | Outperform |
| Dec-16-24 | Upgrade | Stifel | Hold → Buy |
| Oct-10-24 | Resumed | Raymond James | Mkt Perform |
| Oct-07-24 | Downgrade | Cantor Fitzgerald | Overweight → Neutral |
| Dec-13-23 | Initiated | Citigroup | Buy |
| Nov-20-23 | Resumed | JP Morgan | Overweight |
| Oct-24-23 | Resumed | Cantor Fitzgerald | Overweight |
| Sep-06-23 | Initiated | B. Riley Securities | Buy |
| Jan-30-23 | Initiated | SVB Securities | Outperform |
| Dec-05-22 | Initiated | Cowen | Outperform |
| Nov-02-22 | Upgrade | BTIG Research | Neutral → Buy |
| Nov-02-22 | Initiated | BofA Securities | Buy |
| Jun-23-22 | Initiated | Berenberg | Buy |
| Dec-10-21 | Resumed | Raymond James | Mkt Perform |
| Sep-21-21 | Initiated | Oppenheimer | Outperform |
| Sep-01-21 | Initiated | SMBC Nikko | Outperform |
| May-18-21 | Initiated | UBS | Buy |
| Feb-26-21 | Reiterated | H.C. Wainwright | Buy |
| Feb-10-21 | Upgrade | Cantor Fitzgerald | Neutral → Overweight |
| Nov-11-20 | Reiterated | H.C. Wainwright | Buy |
| Oct-16-20 | Downgrade | BTIG Research | Buy → Neutral |
| Sep-14-20 | Resumed | JP Morgan | Overweight |
| Aug-20-20 | Reiterated | H.C. Wainwright | Buy |
| Mar-13-20 | Upgrade | Evercore ISI | In-line → Outperform |
| Feb-28-20 | Upgrade | Wedbush | Neutral → Outperform |
| Feb-24-20 | Initiated | Jefferies | Buy |
| Feb-19-20 | Initiated | Stifel | Hold |
| Jan-27-20 | Upgrade | Goldman | Neutral → Buy |
| Sep-26-19 | Initiated | Wedbush | Neutral |
| Sep-13-19 | Initiated | Nomura | Buy |
| Aug-09-19 | Initiated | BTIG Research | Buy |
| Jun-26-19 | Initiated | H.C. Wainwright | Buy |
| Nov-15-18 | Initiated | Cantor Fitzgerald | Overweight |
| Nov-12-18 | Initiated | Janney | Buy |
| Mar-12-18 | Downgrade | Evercore ISI | Outperform → In-line |
| Jan-02-18 | Initiated | Evercore ISI | Outperform |
| Jan-02-18 | Initiated | Goldman | Neutral |
| Jan-02-18 | Initiated | JP Morgan | Overweight |
| Jan-02-18 | Initiated | Morgan Stanley | Overweight |
View All
Denali Therapeutics Inc Stock (DNLI) Latest News
Can RARE's Approved Product Portfolio Drive Its Next Growth Phase? - Zacks Investment Research
Alector, Inc. (ALEC) Stock Price, News, Quote & History - Yahoo Finance
Denali Therapeutics (DNLI) Stock Looks Stretched On Fair Value Yet Reasonable On Book Value - simplywall.st
The Technical Signals Behind (DNLI) That Institutions Follow - Stock Traders Daily
Denali at Cantor global healthcare conference: launch gains traction By Investing.com - Investing.com India
Denali at Cantor global healthcare conference: launch gains traction By Investing.com - Investing.com UK
Denali Therapeutics (DNLI) Institutional Ownership 2026 $DNLI - MarketBeat
Denali Therapeutics Insider Transactions: Officer Peter Scott Chin to Sell 1,654 Shares, Director Nancy Thornberry Sells 11,439 Shares (NASDAQ: DNLI) - kalkinemedia.com
Denali Therapeutics director sells $261,928 in stock By Investing.com - Investing.com UK
Denali Therapeutics director sells $261,928 in stock By Investing.com - Investing.com South Africa
Denali Therapeutics director sells $261,928 in stock - Investing.com
Denali Therapeutics director sells $261,928 in stock By Investing.com - Investing.com Canada
Denali Therapeutics director sells $261,928 in stock By Investing.com - Investing.com Nigeria
Denali Therapeutics director sells $261,928 in stock - Investing.com
Denali Therapeutics (NASDAQ: DNLI) holder to sell shares to cover tax on stock units - Stock Titan
Denali Therapeutics Director Nancy Thornberry Executes Two Stock Sales Under Rule 10b5-1 Plan - kalkinemedia.com
Denali Therapeutics Insider Sold Shares Worth $261,929, According to a Recent SEC Filing - marketscreener.com
Denali Therapeutics Insider Sold Shares Worth $261,929, According to a Recent SEC Filing - Yahoo Finance
Director Nancy Thornberry plans Denali (NASDAQ: DNLI) stock sale - Stock Titan
Denali Therapeutics (NASDAQ: DNLI) exec plans 2,768-share Rule 144 sale - stocktitan.net
Denali (DNLI) Session: Finishes 2.89% Lower at $24.20; Technical View: Price Remains Between $22.99 Support and $25.41 ResistanceOBV Trend Line - vinanet.vn
Denali Therapeutics (DNLI) Stock Dropped, So Why Is It Drawing Fresh Attention? - sahmcapital.com
Denali Therapeutics (DNLI) Q2 2026 Earnings Call Transcript - AOL.com
145,045 Shares in Denali Therapeutics Inc. $DNLI Purchased by Great Lakes Advisors LLC - MarketBeat
Denali’s DNL921 Trial: Early Alzheimer’s Safety Data That Could Shape Long-Term Upside - TipRanks
DNLI Stock Gains 33.1% in Three Months: Buy, Sell or Hold the Stock? - TradingView
Edmond DE Rothschild Holding S.A. Invests $4.25 Million in Denali Therapeutics Inc. $DNLI - MarketBeat
Denali (DNLI) Financial Update: The Available Earnings Metric Delivers a Miss for This Review; Market Reaction: Shares Finish 3.25% UpDividend Increase Stocks - vinanet.vn
Denali Therapeutics: Bullish On AVLAYAH And Their Prospects (NASDAQ:DNLI) - Seeking Alpha
Bank of America Corp DE Boosts Stock Position in Denali Therapeutics Inc. $DNLI - MarketBeat
Denali Therapeutics (DNLI) Could Be 42% Undervalued Following Its Earnings Report - Sahm
SCS Capital Management LLC Takes Position in Denali Therapeutics Inc. $DNLI - MarketBeat
Denali Therapeutics CEO Ryan J. Watts Donates 32,220 Shares to Donor Advised Fund - Kalkine Media
Denali Therapeutics Inc.: Fundamental Analysis and Financial Ratings | DNLI | US24823R1059 - marketscreener.com
Denali Therapeutics (NASDAQ:DNLI) Insider Sells $71,624.99 in Stock - MarketBeat
Denali Therapeutics (DNLI) Q2 2026 Earnings Call Transcript - The Globe and Mail
Denali Therapeutics: AVLAYAH Converts A Platform Story Into A Commercial One (NASDAQ:DNLI) - Seeking Alpha
Sei Investments Co. Purchases Shares of 52,235 Denali Therapeutics Inc. $DNLI - MarketBeat
Denali Therapeutics (NASDAQ:DNLI) Shows Perfect Technical Setup for a Breakout - ChartMill
J.P. Morgan Maintains Denali Therapeutics(DNLI.US) With Buy Rating, Maintains Target Price $29 - Moomoo
Equities Analysts Set Expectations for DNLI Q3 Earnings - MarketBeat
E. Ohman J or Asset Management AB Acquires New Shares in Denali Therapeutics Inc. $DNLI - MarketBeat
Denali Therapeutics (DNLI) holder to sell 2,857 restricted shares via broker - Stock Titan
Baillie Gifford Trims Denali Therapeutics (DNLI) Stake in June R - GuruFocus
Weekly Recap: Q2 revenue, big net loss and DNL126 Phase 3 with 2027 BLA - TradingView
Denali climbs past Avlayah expectations with $3.6M in revenue - BioSpace
(DNLI) Movement Within Algorithmic Entry Frameworks - Stock Traders Daily
The Manufacturers Life Insurance Company Lowers Stock Holdings in Denali Therapeutics Inc. $DNLI - MarketBeat
Denali Therapeutics (NASDAQ:DNLI) Posts Earnings Results, Misses Estimates By $0.17 EPS - MarketBeat
A Quick Look at Today's Ratings for Denali Therapeutics(DNLI.US), With a Forecast Between $31 to $42 - Moomoo
Denali Therapeutics Inc Stock (DNLI) Financials Data
Revenue
Net Income
Cash Flow
EPS
Denali Therapeutics Inc Stock (DNLI) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Chin Peter Scott | Officer |
Sep 04 '26 |
Proposed Sale |
22.29 |
1,654 |
36,867 |
0 |
| Thornberry Nancy | Director |
Sep 02 '26 |
Sale |
22.90 |
11,439 |
261,929 |
19,686 |
| NANCY THORNBERRY | Director |
Sep 02 '26 |
Proposed Sale |
23.27 |
11,439 |
266,128 |
0 |
| Schuth Alexander O. | COFO and Secretary |
Sep 01 '26 |
Sale |
23.44 |
2,768 |
64,882 |
278,995 |
| ALEXANDER SCHUTH | Officer |
Sep 01 '26 |
Proposed Sale |
23.76 |
2,768 |
65,768 |
0 |
| Schuth Alexander O. | COFO and Secretary |
Aug 11 '26 |
Sale |
25.07 |
2,857 |
71,625 |
281,763 |
| Schuth Alexander O. | Officer |
Aug 11 '26 |
Proposed Sale |
25.07 |
2,857 |
71,624 |
0 |
| CAROLE HO | Former Affiliate |
Feb 05 '26 |
Proposed Sale |
20.29 |
39,490 |
801,394 |
0 |
| CAROLE HO | Former Affiliate |
Feb 04 '26 |
Proposed Sale |
21.18 |
150,000 |
3,176,970 |
0 |
| CAROLE HO | Former Affiliate |
Feb 03 '26 |
Proposed Sale |
22.16 |
150,000 |
3,324,060 |
0 |
1.41%
2.70%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):